Document Detail


Riociguat: PATENT-1 Study.
MedLine Citation:
PMID:  25405174     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat to treat pulmonary arterial hypertension in adults. Support for the approval of riociguat comes from the recently published PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1) study.
Authors:
Karim Said
Related Documents :
1279294 - Neuropeptide y inhibits relaxation of guinea pig cerebral, coronary, and uterine arteri...
20639684 - Dilation of epicardial coronary arteries by the g protein-coupled estrogen receptor ago...
2923194 - Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol...
3922024 - Endothelium influences coronary and aortic vasomotion by release of an unstable humoral...
19756564 - Technical feasibility of 2d-3d coregistration for visualization of self-expandable micr...
9581904 - Adenoviral gene transfer in arteries of hypercholesterolemic nonhuman primates.
Publication Detail:
Type:  Journal Article     Date:  2014-06-18
Journal Detail:
Title:  Global cardiology science & practice     Volume:  2014     ISSN:  2305-7823     ISO Abbreviation:  Glob Cardiol Sci Pract     Publication Date:  2014  
Date Detail:
Created Date:  2014-11-18     Completed Date:  2014-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101613130     Medline TA:  Glob Cardiol Sci Pract     Country:  Qatar    
Other Details:
Languages:  eng     Pagination:  31-5     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Macitentan in pulmonary arterial hypertension: The SERAPHIN trial.
Next Document:  3D-modelling of transient left bronchial obstruction following bidirectional superior cavopulmonary ...